Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)
NCT ID: NCT05088733
Last Updated: 2021-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
120 participants
INTERVENTIONAL
2020-07-01
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Yang Yin Fu Zheng Jie Du therapy
Yang Yin Fu Zheng Jie Du therapy
Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Routine medical care
Routine medical care
Routine medical care
Routine medical care
Routine medical care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yang Yin Fu Zheng Jie Du therapy
Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Routine medical care
Routine medical care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who tested positive for hepatitis B surface antigen (HBsAg) for \>6 months
* Meet the criteria of anemia
* Ages Eligible for Study: ≤75 years old;
* Informed consent from the patient.
Exclusion Criteria
* History of blood transfusion within 3 months before enrollment;
* Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD;
* Serious problem of heart, lung, or kidney with severe dysfunction;
* Pregnant or child breast feeding women;
* Mental or cognitive disorders;
* Participating in other drug trials;
* Who are allergic to the study drug.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Ditan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhiyun Yang
Archiater, Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhiyun Yang
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zhiyun Yang, doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BJDHYZY
Identifier Type: -
Identifier Source: org_study_id